16 September 2026 editorial review · Item
Metformin as an adjunct in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Metformin as an adjunct in T1D
Scope and findings: Added in the second discovery pass. An off-label adjunct with modest weight effects but no sustained glucose-control benefit in the large REMOVAL trial. It remains alongside insulin, with tolerability and patient selection limiting its role. Numerical claims are tied to the cited product specifications or named study, and editorial scores do not represent measured comparative performance.
Primary sources checked:
Limits: Scope is the specific claims documented in the new record. Local stock, payer rules, every hardware variant and unreported head-to-head outcomes are not verified. Regulatory status, manufacturer marketing and clinical performance are distinct.
Thriving evidence review — 16 September 2026
Additional label scope: Current DailyMed label inspected for type2 indication, renal/acidosis contraindications, lactic-acidosis boxed warning and vitaminB12 monitoring. Added these safety caveats without replacing REMOVAL trial-specific findings.
Limits: Local prescribing and stock not verified.